Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

20.00 -0.80 (-3.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 987,199
Open 20.85
Bid (Size) 20.00 (3)
Ask (Size) 21.00 (2)
Prev. Close 20.80
Today's Range 19.99 - 20.85
52wk Range 19.44 - 39.83
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
From Arrowhead Pharmaceuticals, Inc
Via Business Wire

Performance

YTD
-35.50%
-35.50%
1 Month
-19.29%
-19.29%
3 Month
-26.58%
-26.58%
6 Month
-28.29%
-28.29%
1 Year
-25.01%
-25.01%

More News

Read More
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q3 2024
Via InvestorPlace
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Via InvestorPlace
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies
Via Benzinga
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Via Benzinga
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.